A Cross-Sectional Study of Human Immunodeficiency Virus-Associated Neurocognitive Deficit in Central India.
Cureus, ISSN: 2168-8184, Vol: 13, Issue: 10, Page: e18776
2021
- 22Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures22
- Readers22
- 22
Article Description
Background With the advent of modern era of combination antiretroviral therapy (cART) and increased longevity of people living with human immunodeficiency virus (PLHIV), human immunodeficiency virus-associated neurocognitive disorder (HAND) is commonly observed. This study explores the prevalence of HAND and the demographic and treatment variables in people with HAND, in Central India. Research methodology PLHIV on cART visiting HIV clinic underwent screening for substance abuse using CAGE-AID, and depression using PHQ-2 followed by PHQ-9. The screening rules out overt conditions which might interfere with cognitive abilities of the individual and thereby act as confounding factor. Thus, a sample population of 96 was obtained, on whom International HIV Dementia Scale (IHDS) was applied to screen for dementia. Out of 96, 16 individuals detected to suffer from HAND. Quality of Life was assessed by Patient's Assessment of Own Functioning Inventory (PAOFI). Results Prevalence of HAND was estimated to be 16/96 (16.66%). It was more common amongst unmarried individuals (p < 0.001) and lower educational status (p < 0.01) among social variables; while shorter duration of ART (<3 years) (p < 0.01) and lower CD4 nadir (≤200 cell/mm; p<0.01) showed significant correlation among clinical variables. PAOFI revealed significant association between HAND and quality of life (p-value < 0.01, CI = 95%). Modified Mental State Examination (3MS), which determines cognitive ability in various domains based on tasks, was mostly affected for - similarities and read and obey (for 43.75% population). Conclusion Social and clinical variables play a significant role in development of HAND. Routine screening for HAND in PLHIV will help in early identification and management of the disease. The quality of life for those suffering from the burden of HIV and HAND can be significantly improved if approached and treated early in the course of the disease.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know